日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy

筛选适合接受钇-90微球选择性内放射治疗的肝癌患者人群

Liang, Licong; Liang, Yuchan; Huang, Wensou; Guo, Yongjian; Huang, Jingjun; Zhou, Jingwen; Lin, Liteng; Nie, Xinxin; Cai, Mingyue; Zhu, Kangshun

SIRT or TACE in combination with Lenvatinib and PD-(L)1 inhibitor in high tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched study

SIRT 或 TACE 联合乐伐替尼和 PD-(L)1 抑制剂治疗高肿瘤负荷肝细胞癌:一项多中心、回顾性、倾向评分匹配研究

Huang, Jingjun; Niu, Huimin; Zhang, Hui; Cai, Mingyue; Wang, Zhiheng; Guo, Yongjian; Liang, Licong; Lin, Liteng; Yang, Tingqi; Huang, Jiabai; Liang, Yuchan; Guo, Zhaoxiong; Zhou, Jingwen; Huang, Wensou; Zhu, Kangshun

Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study

索拉非尼联合替雷利珠单抗和经动脉化疗栓塞术治疗晚期肝细胞癌:一项 II 期研究

Liang, Licong; Zhou, Jingwen; Huang, Jingjun; Guo, Yongjian; Zhou, Zhimei; Chen, Ye; Lin, Liteng; Hong, Xiaoyang; Shi, Wenbo; Lin, Zhaoyi; Liu, Juan; Zhu, Kangshun; Huang, Wensou; Cai, Mingyue

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial

多那非尼联合信迪利单抗治疗晚期肝细胞癌:一项单臂 II 期试验

Hong, Xiaoyang; Guo, Yongjian; Shi, Wenbo; Zhu, Kangshun; Liang, Licong; Lin, Liteng; Chen, Ye; Zhou, Jingwen; Huang, Jingjun; Huang, Jiabai; Wu, Yaozhu; Huang, Wensou; Cai, Mingyue

Exploratory investigation of dose calculation and tumor-feeding artery identification using dual CBCT in selective internal radiation therapy with Yttrium-90 microspheres

利用双锥形束CT进行钇-90微球选择性内放射治疗的剂量计算和肿瘤供血动脉识别的探索性研究

Guo, Zhaoxiong; Liang, Yuchan; Li, Tingfeng; Li, Ao; Zhu, Kangshun; Guo, Yongjian; Wang, Wenxin; Huang, Wensou

Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study

乐伐替尼联合载药微球经动脉化疗栓塞术(伴或不伴肝动脉灌注化疗)治疗伴有门静脉主要肿瘤血栓形成的大于7厘米的肝细胞癌:一项多中心回顾性队列研究

Cai, Mingyue; Liang, Licong; Zhang, Jian; Chen, Nianping; Huang, Wensou; Guo, Yongjian; Hong, Xiaotao; Lin, Liteng; Liu, Yaohong; Dan, Cao; Deng, Haihui; Liu, Xiaoguang; Zhou, Jingwen; Chen, Ye; Chen, Huanwei; Zhu, Kangshun

Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension

微生物来源的尿石素 A 靶向 GLS1 以抑制谷氨酰胺分解并减轻肝硬化门脉高压

Rui Li, Zhile Liu, Wensou Huang, Yongjian Guo, Chan Xie, Hongmei Wu, Jianxin Liu, Xiaoyang Hong, Xiaobin Wang, Jingjun Huang, Mingyue Cai, Zhaoxiong Guo, Licong Liang, Liteng Lin, Kangshun Zhu

T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma

T细胞介导的靶向递送他达拉非可通过调节免疫抑制和多胺代谢来克服肝细胞癌中的免疫检查点阻断耐药性。

Xiaobin Wang # ,Qiaoyun Zhang # ,Jingwen Zhou # ,Zecong Xiao # ,Jianxin Liu ,Shaohui Deng ,Xiaoyang Hong ,Wensou Huang ,Mingyue Cai ,Yongjian Guo ,Jingjun Huang ,Yong Wang ,Liteng Lin ,Kangshun Zhu

Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases

抑制CEMIP可通过降低肺转移灶的硬度来增强索拉非尼对转移性肝细胞癌的疗效。

Liu, Mingyu; Xie, Lulu; Zhang, Yuying; Chen, Jianning; Zhang, Xiang; Chen, Ye; Huang, Wensou; Cai, Mingyue; Liang, Licong; Lai, Miaoling; Huang, Jingjun; Guo, Yongjian; Lin, Liteng; Zhu, Kangshun

HBV suppresses macrophage immune responses by impairing the TCA cycle through the induction of CS/PDHC hyperacetylation

HBV通过诱导CS/PDHC过度乙酰化来损害TCA循环,从而抑制巨噬细胞的免疫反应。

Bei, Jiaxin; Chen, Ye; Zhang, Qianbing; Wang, Xiaobin; Lin, Liteng; Huang, Jingjun; Huang, Wensou; Cai, Mingyue; Cai, Weiguo; Guo, Yongjian; Zhu, Kangshun